Abstract
Paediatric diffuse large B-cell lymphoma (DLBCL) is a rare but aggressive form of non-Hodgkin lymphoma. Although rituximab has significantly improved outcomes in both adult and paediatric patients, challenges remain for those who relapse or are resistant to the initial treatment. This review examines recent clinical trials investigating various immunotherapies for relapsed or refractory (R/R) paediatric DLBCL, including immunomodulatory agents, monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, checkpoint inhibitors, and chimeric antigen receptor (CAR) T-cell therapy. A comprehensive search identified forty-eight relevant trials with significant focus on CAR-T cell therapy. This review highlights the potential benefits of these novel therapies for improving the survival rate and quality of life of paediatric patients. However, it also underscores the need for increased international collaboration and paediatric-specific research to address the unique challenges in treating this vulnerable population. Future directions include the integration of personalised medicine and development of chemotherapy-free regimens.
| Original language | English |
|---|---|
| Article number | 100228 |
| Number of pages | 8 |
| Journal | EJC Paediatric Oncology |
| Volume | 5 |
| Early online date | 28 Mar 2025 |
| DOIs | |
| Publication status | Published - 1 Jun 2025 |
Keywords
- paediatric diffuse large B-cell lymphoma
- immune-mediated therapies
- immunotherapy
- immunomodulatory agents
- bispecific antibodies
- checkpoint inhibitors
- antibody drug conjugates
- chimeric antigen receptor T-cell therapy